Advocacy

Legislation

Florida: HB 697

Prescription Reduction Incentives and Competition Enhancement Act
– Implements international reference pricing of prescription drugs
– Implements certain PBM reforms
– Restricts mid-year health plan formulary changes

12/9/25 – Introduced
12/16/25 – Referred to Health & Human Services and Budget Committees
12/16/25 – Assigned to Health Care Facilities & Systems Subcommittee

Read the Bill

Michigan: SB 3

Prescription Drug Cost and Affordability Review Act
Establishes a Prescription Drug Affordability Board.

1/8/25 – Introduced and Referred to Committee on Finance, Insurance, and Consumer Protection
4/24/25 – Reported Favorably with Substitute
4/24/25 – PASSED Senate: 20 YES – 15 NO
4/24/25 – Referred to House Committee on Government Operations

Read the Bill

Implementation

Colorado Prescription Drug Affordability Board

Board Website

Next Regular Meeting: January 9, 2026 – 10AM MST
Register HERE
Agenda TBD

Previous Findings:
Trikafta – Not Unaffordable
Genvoya – Not Unaffordable
Enbrel – Unaffordable
Stelara – Unaffordable
Cosentyx – Unaffordable

In October 2025, the Board set an upper payment limit for Enbrel based on Medicare’s Maximum Fair Price. Rulemaking hearings for Stelara and Cosentyx are forthcoming.

Maryland Prescription Drug Affordability Board

Board Website

Next Regular Board Meeting: January 26, 2026
Agenda TBD

Next PDASC Meeting: December 15, 2025 – 2PM EST

At the May 2024 meeting, the PDAB selected six drugs for cost review:
Farxiga
Jardiance
Ozempic
Trulicity
Dupixent
Skyrizi

In July, 2025, the PDAB voted that Farxiga and Jardiance may cause affordability challenges. In November 2025, the PDAB voted that Ozempic and Trulicity may cause affordability challenges. Cost reviews for other selected drugs remain ongoing.

Minnesota Prescription Drug Affordability Board

Board Website

Next Regular Board Meeting: November 18, 2025 – 10:30AM CST
Join HERE

Oregon Prescription Drug Affordability Board

Board Website

Next Meeting: December 17 – 8AM PST
Register HERE
Agenda HERE

In June 2024, the board voted to pause current assessments in order to reevaluate their process and data, with assessments resuming in 2025. In March 2025, the PDAB selected 27 drugs to review. In June 2025, the list was narrowed to 23 drugs. It plans to review five or more drugs each month July through October, but has extended the deadline to publish its final report on affordability for the drugs to March 2026.

2024 Findings:
Ozempic – May Cause Affordability Challenges (2/21)
Trulicity – May Cause Affordability Challenges (2/21)
Shingrix- Reviewed, No Motion to Add to List of Drugs That May Cause Affordability Challenges (2/21)
Inflectra – Removed from Affordability Review (5/15)
Skyrizi – Removed from Affordability Review (5/15)